Prediction Case File
YouTubeEvaluation Complete

Healthcare stocks have taken a beating in 2025, but I think that has created opportunities for long-term investors to buy at bargain prices.

1 extracted signal · 1 resolved · 0 still active

Parkev Tatevosian, CFA profile imageParkev Tatevosian, CFAIndependent analyst profile
Source published
15 Sept 2025, 16:45 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for Healthcare stocks have taken a beating in 2025, but I think that has created opportunities for long-term investors to buy at bargain prices.
Source overview

AI-generated source summary

The video discusses three undervalued healthcare stocks: Eli Lilly (LLY), Novo Nordisk (NOVOB), and Pfizer (PFE). LLY is trading at a forward P/E of 27, NOVOB at 15, and PFE at 8.5. Revenue growth over the past decade has been positive for all three, with LLY and NOVOB demonstrating revenue growth due to weight loss and diabetes treatments. Operating profit margins are 48% for NOVOB and 43% for LLY with a return on invested capital around 30% .PFE's operating margin now at 28% and the returns on invested capital is 9.3%. The speaker highlights that an ability to research and develop new treatments. All the 3 stocks are a long-term opportunities.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
1
Extracted from this source
Open
0
Still being tracked
Successful
1
Resolved successfully
Failed
0
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
100%
1 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  3. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

  4. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  5. Market predictions extracted

    1 eligible signal linked to this case.

  6. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

Analyst snapshot

Parkev Tatevosian, CFA

Platform-wide history, separate from this source evaluation.

Reliability
41.8
Tracked signals
1293
Historical success
25.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail